Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN060 in venous thromboembolism prevention after total knee arthroplasty
NCT06180889Phase 2Active, not recruiting
- Sponsor
- Alphamab Oncology
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lofacimig (4 arms), sponsored by Alphamab Oncology. Primary endpoint: Composite endpoint of asymptomatic DVT, symptomatic DVT, non-fatal PE, fatal PE, unexplained death at 14 days. Started Dec 2023; status: active, not recruiting.
02
Drugs
lofacimig
Beyond the preview
Go deeper on NCT06180889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06180889.